Cardiology

The CGTLive™ Cardiology specialty topic page contains video interviews with key opinion leaders in the field of cardiology and up-to-date clinical news coverage on the latest cardiology gene and cell therapies for heart disease. It houses information on relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for heart conditions.

Latest News

Around the Helix: Cell and Gene Therapy Company Updates – June 11, 2025
Around the Helix: Cell and Gene Therapy Company Updates – June 11, 2025

June 11th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Nuevocor Snags IND Clearance for Gene Therapy Trial in LMNA DCM
Nuevocor Snags IND Clearance for Gene Therapy Trial in LMNA DCM

June 11th 2025

Data Roundup: May 2025 Features Updates from ASGCT, ASCO, and More
Data Roundup: May 2025 Features Updates from ASGCT, ASCO, and More

June 8th 2025

Heather Landau, MD, the MSKCC Amyloidosis Program director and the NEXICART-2 principal study investigator
Heather Landau, MD, on Evaluating CAR-T NXC-201 for Light Chain Amyloidosis

June 5th 2025

Around the Helix: Cell and Gene Therapy Company Updates – June 4, 2025
Around the Helix: Cell and Gene Therapy Company Updates – June 4, 2025

June 4th 2025

Video Interviews

More News

Iovance Biotherapeutics’ Lifileucel Produces Durable Responses in 5-Year Analysis of Advanced Melanoma Data

Iovance Biotherapeutics’ Lifileucel Produces Durable Responses in 5-Year Analysis of Advanced Melanoma Data

Noah Stansfield
June 3rd 2025

The analysis included 153 patients with a median follow-up of 57.8 months.

Heather Landau, MD, the MSKCC Amyloidosis Program director and the NEXICART-2 principal study investigator

Immix Biopharma’s CAR-T NXC-201 Effects Deep Hematologic Responses in Light Chain Amyloidosis

Noah Stansfield
June 3rd 2025

Following treatment with NXC-201, all 7 patients (100%) showed normalized pathological disease markers.

Around the Helix: Cell and Gene Therapy Company Updates – May 28, 2025

Around the Helix: Cell and Gene Therapy Company Updates – May 28, 2025

Noah Stansfield
May 28th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patient Dies After Treatment With Rocket Pharmaceuticals’ Danon Disease Gene Therapy RP-A501 in Phase 2 Trial

Patient Dies After Treatment With Rocket Pharmaceuticals’ Danon Disease Gene Therapy RP-A501 in Phase 2 Trial

Noah Stansfield
May 27th 2025

The patient’s death occurred after an acute systemic infection and was associated with an unexpected SAE of clinical complications related to capillary leak syndrome.

Around the Helix: Cell and Gene Therapy Company Updates – May 21, 2025

Around the Helix: Cell and Gene Therapy Company Updates – May 21, 2025

Noah Stansfield
May 21st 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Rocket’s PKP2-Arrhythmogenic Cardiomyopathy Gene Therapy RP-A601 Improves or Stabilizes Heart Function in Phase 1 Trial

Rocket’s PKP2-Arrhythmogenic Cardiomyopathy Gene Therapy RP-A601 Improves or Stabilizes Heart Function in Phase 1 Trial

Noah Stansfield
May 16th 2025

The data presented came from 3 patients treated in the trial who had a follow-up time of up to 12 months.

Around the Helix: Cell and Gene Therapy Company Updates – May 14, 2025

Around the Helix: Cell and Gene Therapy Company Updates – May 14, 2025

Noah Stansfield
May 14th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – May 7, 2025

Around the Helix: Cell and Gene Therapy Company Updates – May 7, 2025

Noah Stansfield
May 7th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: April 2025 Features Updates for Cardiomyopathy Gene Therapy, Myasthenia Gravis CAR-T, and More

Data Roundup: April 2025 Features Updates for Cardiomyopathy Gene Therapy, Myasthenia Gravis CAR-T, and More

Noah Stansfield
May 2nd 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Around the Helix: Cell and Gene Therapy Company Updates – April 30, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 30, 2025

Noah Stansfield
April 30th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – April 23, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 23, 2025

Noah Stansfield
April 23rd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025

Noah Stansfield
April 16th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Verve Therapeutics’ Base Editing Therapy VERVE-102 Reduces LDL-C in Patients With HeFH and CAD

Verve Therapeutics’ Base Editing Therapy VERVE-102 Reduces LDL-C in Patients With HeFH and CAD

Noah Stansfield
April 15th 2025

Verve noted that a patient treated at the 0.6 mg/kg dose showed the maximum decrease in LDL-C levels: 69%.

Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy

Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy

Noah Stansfield
April 10th 2025

The data come from patients treated across 2 studies.

Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025

Noah Stansfield
April 9th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Noah Stansfield
April 2nd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

Noah Stansfield
April 1st 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Noah Stansfield
April 1st 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Noah Stansfield
March 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Secretome Therapeutics Doses First Patient in Phase 1 Trial for Heart Failure Cell Therapy STM-01

Secretome Therapeutics Doses First Patient in Phase 1 Trial for Heart Failure Cell Therapy STM-01

Noah Stansfield
March 25th 2025

According to Secretome, the first-in-human, open-label trial is the first trial to assess an allogeneic stem cell therapy product for HFpEF.

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

Noah Stansfield
March 20th 2025

The product is marketed under the name Amvuttra.

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

Noah Stansfield
March 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

Noah Stansfield
March 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

CGTLive Staff
March 6th 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Noah Stansfield
March 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Noah Stansfield
February 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Noah Stansfield
February 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 12, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 12, 2025

Noah Stansfield
February 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis

Noah Stansfield
February 10th 2025

The therapy is currently being evaluated for AL amyloidosis in the phase 1b/2 NEXICART-2 clinical trial (NCT06097832) in the United States.

Around the Helix: Cell and Gene Therapy Company Updates – February 5, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 5, 2025

Noah Stansfield
February 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

1234567>
© 2025 MJH Life Sciences

All rights reserved.